Dyadic Logo Current.jpg
Dyadic Reports 2023 Full Year Results and Recent Company Progress
March 28, 2024 16:00 ET | Dyadic International, Inc.
Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical...
cmi_logo.png
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 28, 2024 15:30 ET | Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
Dyadic Logo Current.jpg
Dyadic Announces Change in Board and Management Leadership Roles
March 28, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
US Pharmaceutical Market
US Pharmaceutical Market Review 2020-2023 and Forecast 2024-2030: A $1.28 Trillion Opportunity, Driven by the Rising Adoption of AI-based Tools for Drug Discovery
March 27, 2024 08:34 ET | Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "US Pharmaceutical Market Size and Forecast (2020 - 2030), Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product...
Dyadic Logo Current.jpg
Dyadic to Attend Industry Events in April
March 27, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
22157.jpg
Global Vaccines Market Research Report 2024: Focus on Commercialized and Developmental Vaccines
March 21, 2024 07:40 ET | Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "The World Market for Vaccines, 2024" report has been added to ResearchAndMarkets.com's offering. The World Market for Vaccines, 2024 offers the...
image1 (1).png
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
March 19, 2024 07:30 ET | Evaxion Biotech
The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI and machine learning technologiesAI-Immunology™ outcompetes...
22157.jpg
Monkeypox Vaccine and Treatment Market Research Report 2024: Global Industry Analysis, Trends, Market Size, and Forecasts 2022-2030
March 18, 2024 05:57 ET | Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Monkeypox Vaccine and Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030" report has been added to ...
22157.jpg
MEDI8897 (Nirsevimab) Market Landscape 2024-2032: Mechanism, Dosage, Regulatory Milestones, Global R&D, Patents, Sales Forecast, Emerging Therapies
March 15, 2024 09:01 ET | Research and Markets
Dublin, March 15, 2024 (GLOBE NEWSWIRE) -- The "MEDI8897 Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report offers...
Dyadic Logo Current.jpg
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
March 14, 2024 16:30 ET | Dyadic International, Inc.
JUPITER, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused building...